Improving The Lives Of Young People With Type 1 Diabetes Using State-of-the-Art Therapies
Funder
National Health and Medical Research Council
Funding Amount
$2,599,598.00
Summary
T1D profoundly affects the lives of an increasing number of young people and their families. H The proposed centre acknowledges these challenges and recognises the urgent need for a comprehensive and holistic approach involving a broad range of expertise, methodologies and collaboration. The centre will utilize clinical expertise of the CI’s, generating new knowledge for the successful development and use of technology in closed loop and semi-closed systems in young people with T1D.
Understanding The Early-life Pathways For Adult Type 2 Diabetes Using Existing Data From Seven Cohorts Of The International Childhood Cardiovascular Cohort (i3C) Consortium
Funder
National Health and Medical Research Council
Funding Amount
$336,419.00
Summary
This project will allow us to determine the role that child factors play in the development of diabetes. We will do this using information that has been collected from individuals at several ages extending from childhood to adulthood, somewhat like the “Up” TV series. The project’s findings could lead to improvements in the way we identify people who are at risk of having adult diabetes. By doing so, we could begin programs to stop the young from being struck down by this debilitating disease.
Bisphosphonate Therapy With Zoledronate Or Tenofovir Switching To Improve Low Bone Mineral Density In HIV-Infected Adults: A Strategic, Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$716,300.00
Summary
Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.